Clinical Trials Logo

Filter by:
NCT ID: NCT04612790 Terminated - Bullous Pemphigoid Clinical Trials

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

FJORD
Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).

NCT ID: NCT04612751 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

TROPION-Lung04
Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT04612725 Terminated - Clinical trials for Chronic Spontaneous Urticaria

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

ARROYO
Start date: October 27, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.

NCT ID: NCT04612062 Completed - Atopic Dermatitis Clinical Trials

A First-in-Human Study of CEE321 in Adult Subjects

Start date: February 27, 2020
Phase: Phase 1
Study type: Interventional

Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis

NCT ID: NCT04610892 Completed - Clinical trials for Coronary Heart Disease (CHD)

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction

GOLDILOX
Start date: November 4, 2020
Phase: Phase 2
Study type: Interventional

A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.

NCT ID: NCT04609878 Recruiting - Asthma Clinical Trials

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

KALOS
Start date: December 15, 2020
Phase: Phase 3
Study type: Interventional

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care

NCT ID: NCT04609852 Completed - Healthy Volunteers Clinical Trials

A Study to Assess the Safety and Tolerability of E8001 in Healthy Male Participants

Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of E8001 of single ascending dose intravenous infusions in healthy male participants.

NCT ID: NCT04609111 Active, not recruiting - Clinical trials for Acute Coronary Syndrome

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

STOPDAPT-3
Start date: January 29, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coronary intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under the acute coronary syndrome patients.

NCT ID: NCT04609059 Recruiting - Clinical trials for Paroxysmal Atrial Fibrillation

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation

Start date: May 7, 2019
Phase: Phase 2
Study type: Interventional

First-in-Patient Study for sing le dose of M201-A hydrochloride injection in Japanese patients with paroxysmal atrial fibrillation.

NCT ID: NCT04608838 Completed - Clinical trials for Acute Ischemic Stroke

A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)

J-REPAIR
Start date: January 30, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of a single intravenous administration of JTR-161 (allogeneic stem cell product derived from the dental pulp of healthy adult humans) to patients with acute ischemic stroke. This study is comprised of 3 cohorts and conducted in the order of Cohort 1, Cohort 2 and Cohort 3. Cohort 1 Arm-1: JTR-161, 1 × 10^8 cells/subject, 6 subjects Arm-2: Placebo, 2 subjects The Data and Safety Monitoring Board (DSMB) and the Sponsor will decide whether Cohort 2 can be initiated or not. Cohort 2 Arm-1: JTR-161, 3 × 10^8 cells/subject, 6 subjects Arm-2: Placebo, 2 subjects DSMB and the Sponsor will decide whether Cohort 3 can be initiated or not and the dose of JTR-161 in Cohort 3. Cohort 3 Arm-1: JTR-161, 1 × 10^8 cells/subject or 3 × 10^8 cells/subject, 30 subjects Arm-2: Placebo, 30 subjects